Hofseth BioCare ASA: Extraordinary General Meeting completed
Hofseth BioCare ASA: Extraordinary General Meeting completed
Hofseth BioCare ASA held an Extraordinary General Meeting on 20 November
2025. All proposals were resolved as presented in the notice issued on 30
October 2025.
The minutes from the Extraordinary General Meeting are attached.
For further information, please contact:
Jon Olav Ødegård, CEO at HBC
E-mail: [email protected]
About Hofseth BioCare ASA:
HBC is a Norwegian consumer and pet health company founded on the core values of
sustainability, optimal utilization of natural resources and full traceability.
It upcycles the side streams of the salmon industry by taking fresh filleted
salmon and converting it from a waste product into ingredients to improve human
and pet health.
These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,
a whole salmon oil, with all the fatty acid fractions contained in fish, and
CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and
undenatured collagen for bone and joint health.
HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.
This work has also resulted in the granting of a number of patents protecting
these discoveries. It has also led to the discovery of potential therapeutics
and HBC has spun out a biotech-focused company, HBC Immunology (HBCI) has raised
external finance, and the lead program is in prostate cancer followed by ovarian
cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for
asthma.
HBC's headquarters are in Ålesund, Norway with branches in Oslo, London, Zürich
and Palo Alto.
HBC is listed on Oslo Stock Exchange with ticker "HBC".
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act